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Abstract
Background: Current guidelines recommend children be treated for hepatitis C virus (HCV) using the same principles
applied in adults. There are however few published studies which assess the efficacy and safety of HCV therapy in
children.
Methodology/Principal Findings: A systematic review of the literature was completed for studies of any design that
evaluated HCV therapy in children. The primary outcome was sustained virologic response (SVR), with sub-group analysis of
response rates by genotype. There were 4 randomized controlled trials (RCTs) and 31 non-randomized studies, all involving
interferon, pegylated interferon (PEG-IFN), or combinations of these drugs with ribavirin. The SVR rate could not be directly
compared as the populations and interventions differed across studies. Genotype was not reported or differed substantially
from study to study. The overall SVR rate for PEG-IFN and ribavirin ranged from 30 to 100% which is comparable to the rate
in adults. Similar to adults, the SVR rates were significantly higher in children with genotype 2 or 3 compared to genotype 1.
Adverse effects were primarily flu-like symptoms and neutropenia. There were insufficient data to assess the applicability of
the week 12 stop rule (stopping therapy at week 12 if there is less than a 2 log drop in HCV RNA) or the efficacy of
shortening therapy to 24 weeks in children with genotype 2 and 3.
Conclusions/Significance: Current guidelines for the treatment of HCV in children are based on limited data. Further
research is needed to define the optimal therapy for HCV in children.
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Introduction
Treatment guidelines for hepatitis C virus (HCV) infection in
adults are based on a large body of published natural history
studies and randomized controlled trials (RCTs). There is a
relative paucity of data regarding the impact of HCV on the
morbidity and mortality of infected children and few published
studies which assess the efficacy and safety of HCV therapy in
children. Despite this, current guidelines recommend children be
assessed and treated for HCV in a similar manner to adults [1].
The prevalence of HCV infection in children varies widely by
country, ranging from 0% in Japan and 0.4% in Italy to up to
14.5% in Cameroon.[2,3,4] A study performed in the early 1990s
in the United States documented HCV antibodies in 0.2% of
children aged 6 to 12 and 0.4% of children aged 12 to 19 [5]. It is
estimated that 75–80% of children who are antibody positive are
also HCV RNA positive [5].
The natural history of HCV in children is not completely
understood. However, compared to adult infection, spontaneous
clearance is more common and both fulminant hepatitis and
progression of chronic infection to advanced fibrosis and cirrhosis
are less likely [6,7,8,9,10,11]. Despite the overall more favorable
prognosis than in adults, approximately 4 to 6% of children with
chronic HCV infection have evidence of advanced fibrosis or
cirrhosis on liver biopsy [11,12], and 4 to 5 children each year
undergo liver transplantation in the United States for end-stage
liver disease as a consequence of HCV [13].
Despite the significant number of children infected with HCV,
and a clear subset of those who may benefit from HCV therapy,
there is little consensus on when or how to optimally treat children
with HCV infection. A previous meta-analysis examining
interferon monotherapy for pediatric HCV concluded that the
sustained virologic response (SVR) was higher and that therapy
was better tolerated than in adults [14]. Combination therapy with
pegylated interferon (PEG-IFN) and ribavirin has been shown to
be superior to standard interferon monotherapy or combination
therapy with interferon and ribavirin and is the current gold
standard for HCV therapy in adults [1,15,16] but there is a
paucity of pediatric RCTs of this therapy.
This paper represents a comprehensive and systematic review of
evidence specific to children for the treatment of HCV infection.
The primary aim was to determine if there is sufficient evidence to
recommend any ways in which the approach to therapy of
children with HCV should differ from the approach in adults. A
secondary aim was to use this data to serve as a basis to identify
priority areas for future research.
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Searching
A medical research librarian conducted comprehensive searches
in the following electronic databases: MedlineH (1950-April Week
2 2009), Embase (1980 to 2009 Week 16), EBM Reviews –
Cochrane Central Register of Controlled Trials (1
st Quarter 2009),
Web of ScienceH (1900–2009), ScopusH (1966–2009), LILACS
(1982–2009), Biosis PreviewsH (1926–2009), Proquest Dissertations
and Theses (1900–2009) and the ARIF Reviews Database (1996–
2009). No language restrictions were applied. Search strategies
were modified to accommodate the controlled vocabulary and
search language of each database. The search strategy for Medline
appears in Appendix S1. Search strategies for the other databases
are available from the corresponding author.
Unpublished studies were identified by hand searching the
following conference proceedings: North American and European
Societies of Pediatric Gastroenterology and Nutrition (2007–2009),
American Association for the Study of Liver Diseases (2006–2009),
American Gastroenterology Association (2006–2010), European
Association for the Study of the Liver (2007–2010). Ongoing
studies were identified through searches of UMIN-CTR, Current
Controlled Trials and Clinical Trials.gov. Studies were also
located by scanning reference lists of existing systematic reviews
and included studies
Study Selection and Characteristics
The title and abstracts of studies identified by the search were
screened for potential relevance. The full text of all potentially
relevant studies was reviewed to determine if they fulfilled the
eligibility criteria. Studies were included if: 1) they included only
children (#18 years of age) or presented data separately for
children; 2) HCV infection was confirmed by detection of HCV
RNA; 3) details of the treatment regimen were provided; and 4)
data were provided for the sustained virologic response (SVR,
defined as a negative HCV RNA at least 24 weeks after cessation
of therapy) which was the outcome of interest. All interventions for
the treatment of HCV were included, as were all comparisons. We
anticipated that there would be a small number of RCTs meeting
our inclusion criteria; therefore, we chose to include studies of any
design that reported the efficacy or effectiveness of treatment in a
cohort of children infected with HCV.
Validity assessment of randomized controlled trials
All relevant RCTs were assessed for risk of bias independently
by two reviewers (JH, LH) using the Cochrane Risk of Bias (RoB)
tool. The Cochrane RoB tool evaluates six domains including:
sequence generation, allocation concealment, blinding, missing
outcome data, selective outcome reporting, and ‘‘other sources of
bias.’’ Disagreements were resolved through discussion.
Data abstraction
An electronic data extraction form was developed in MS Excel a
priori and used for data entry. Extracted items included
characteristics of the study population and intervention and
control groups, inclusion and exclusion criteria, treatments given,
SVR, and adverse effects. Data from RCTs was extracted by a
single reviewer and checked by a second reviewer. Authors of
RCTs with missing data were contacted for details.
Quantitative data synthesis
There was significant clinical and methodological heterogeneity
across studies in terms of the interventions, comparisons, and study
designs. Therefore, meta-analysis was not appropriate. We
described the studies qualitatively and present detailed results in
evidence tables. The results are presented by study design, i.e.,
RCTs and non-randomized studies with separate analysis for
genotype 1 versus other genotypes where specified.
Results
Flow of included studies
The comprehensive literature search returned a total of 1914
articles (Figure 1). Of these, 4 met the inclusion criteria as
RCTs while 31 met the inclusion criteria as non-randomized
studies.
Study Characteristics - Randomized Controlled Trials
Among the four relevant RCTs, three were peer-reviewed
manuscripts and one was an abstract presented at the 2008
Annual Meeting of the American Association for the Study of
Liver Diseases (Table 1). Three included only pediatric popula-
tions [17,18,19] while one had a mixed pediatric-adult population
[20]. All four RCTs were deemed to have an unclear risk of bias
based on the Cochrane Risk of Bias tool. The RCT by Schwarz et
al. [19] appeared to be the most methodologically rigorous but was
still rated unclear since only the study protocol and abstract were
available for assessment. Sequence generation and allocation
concealment were generally poorly described. Inappropriate
sequence generation and inadequate allocation concealment can
result in overestimates of treatment effects.
Quantitative Data Synthesis - Randomized Controlled
Trials
Two studies conducted in Italy were both published in 1995,
and randomized children up to 14 years of age with biopsy-proven
Figure 1. Systematic review process flowchart.
doi:10.1371/journal.pone.0011542.g001
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regimens in each study as shown in Table 1) versus no treatment
for 12 months. Iorio et al. found that 5 of 11 (45%) treated patients
and 1 of 11 controls (9%) achieved a SVR [18] (Table 2). These
results were borderline statistically significant (p=0.056), likely
due to the small numbers of patients. Bortolotti et al. reported that
SVR was achieved in 9 of 13 (69%) treated patients and 0 of 13
controls (p,0.001) [17]. Almost all treated patients had flu-like
symptoms, and doses of interferon were decreased in 7 of 25
children (28%) due to neutropenia. Therapy was stopped in 3
other children for ALT flares.
Fried et al. studied a mixed pediatric-adult population at US
hemophiliac clinics [20]. Viremic subjects aged 13 years and older
were randomized to interferon alfa-2b and ribavirin versus
interferon monotherapy for 48 weeks. The only outcome data
provided for adolescents was a SVR in 10 of 17 (59%) in those on
combination therapy. The authors were contacted and were not
able to provide SVR rates in adolescents on monotherapy, but
pointed out that only 6 of 57 adults and adolescents combined
(11%) achieved SVR on monotherapy.
A fourth RCT by Schwarz et al. randomized children with
biopsy-proven chronic hepatitis and viremia in Europe, the US,
and South America to PEG-IFN alfa-2a 180ug/1.73m2/week and
ribavirin 15 mg/kg/day versus PEG-IFN alfa- 2a monotherapy
for 48 weeks [19]. Data was extracted from an abstract published
in 2008. SVR was achieved in 29 of 55 (53%) children on
combination therapy and in 12 of 59 (21%) on monotherapy
(p,0.001). Four percent of children on combination therapy and
7% on monotherapy required early discontinuation, presumably
due to adverse events, while 51% on combination therapy and
54% on monotherapy required dose reduction. An abstract from
this study described one child with ischemic retinopathy, one with
uveitis, and one with transient monocular blindness that the
authors attributed to PEG-IFN [21]. The presence of autoanti-
bodies did not alter the SVR rate [22].
Among the four RCTs, viral genotype was only mentioned in
the Schwarz study with SVR being 80% in those with non-
genotype 1 on combination therapy versus 36% on monotherapy.
SVR for those with genotype 1 was 47% on combination therapy
versus 18% on monotherapy.
Table 1. Study design of randomized controlled trials of pediatric HCV therapy.
Author/Year/
Country Entry criteria
Group A
Characteristics
Group B
Characteristics Group A Treatment Group B Treatment
1. Iorio 1995,
Italy [18]
Children with HCV attending liver
diseases clinic 1 to 14 years of
age with chronic hepatitis on
biopsy, elevated ALT for at least
6 months, and anti-HCV antibodies
7 males, 4 females;
7 genotype 1, 5
non-genotype 1
4 males, 6 females;
7 genotype 1, 3
non-genotype 1
Interferon alfa,
3 MU/m
2times
weekly for
12 months
No treatment
2. Bortolotti,
1995, Italy [17]
Children with HCV 2 to 14 years
of age with chronic hepatitis on
biopsy, elevated ALT for at least
6 months, and anti-HCV antibodies
7 males, 7 females;
7 genotype 1, 7
non-genotype 1
5 males, 8 females;
6 genotype 1, 8
non-genotype 1
Interferon alfa-2b
5 MU/m
2 3 times
weekly for 12 months
No treatment
3. Fried 2002,
USA [20]
Adolescents with HCV and
haemophilia 13 to 17 years
of ages and with detectable
HCV-RNA
17 adolescents;
All infected by
transfusion
20 adolescents;
All infected by
transfusion
Interferon alfa-2b 3 MU/m
2
3 times weekly + 1000 mg
ribavirin daily for 48 weeks
Interferon alfa-2b 3
MU/m
2 3 times
weekly for 48 weeks
4. Schwarz
2008, USA [19]
Children with HCV 5 to 17 years
of age with chronic hepatitis on
biopsy and detectable HCV-RNA
34 males, 21 females;
44 genotype 1; 11
non-genotype 1
29 males, 30 females;
48 genotype 1; 11
non-genotype 1
PEG-IFN alfa-2a 180
micrograms/1.73 m
2 + ribavirin
15/mg/kg/day for 48 weeks
PEG-IFN alfa-2a 180
micrograms/1.73 m
2
for 48 weeks
doi:10.1371/journal.pone.0011542.t001
Table 2. Outcome of randomized controlled trials of pediatric HCV therapy.
Author/Year/
Country Group A Therapy Incomplete
Group B Therapy
Incomplete Group A SVR Group B SVR Group A Adverse Effects
Group B
Adverse
Effects
1. Iorio
1995, Italy
Discontinued in 1 child in
first month from ALT flare-up
and in 5 others at 6 months
since no response in ALT
Not applicable as
no therapy given
5 of 11 (45%)
at 30 months
1 of 11 (9%)
at 30 months
Transient influenza-like
syndrome in all patients;
other symptoms included anorexia,
asthenia, irritability, headache,
abdominal pain, and leukopenia
Not reported
2. Bortolotti,
1995, Italy
Discontinued in 2 children
from ALT flare-up, in 1 child
from febrile seizure, and 1
since no response in ALT
Not applicable as
no therapy given
9 of 13 (69%)
at 24 months
0 of 13 (0%)
at 24 months
Transient influenza-like
syndrome in all patients;
Other symptoms included pruritus,
weight loss, and leukopenia
Not reported
3. Fried
2002, USA
Not reported Not reported 10 of 17 (59%)
at 72 weeks
Not reported Not reported Not reported
4. Schwarz
2008, USA
Discontinued in 2 children Discontinued in
4 children
29 of 55 (53%)
at 72 weeks
15 of 59 (21%)
at 72 weeks
Not reported Not reported
doi:10.1371/journal.pone.0011542.t002
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Thirty-one non-randomized studies met the inclusion criteria
(Table S1). Full manuscripts were available for 26 of these studies;
the others were only available in abstract form. One study had a
comparison group: interferon/ribavarin combination therapy
versus interferon monotherapy [23]. The remaining studies were
uncontrolled before-after studies; therefore, 32 treatment groups
were available for analysis.
The studies were published between 1992 and 2010. The
number of participants ranged from 8 to 151 (median: 24). All
studies described one of the following four therapies in various
standardized doses, most commonly 3 or 5 MU/m
2 interferon
thrice weekly or PEG-IFN alfa-2b 1.0 to 1.5 ug/kg/week and
15 mg/kg/day ribavirin:
1) Interferon monotherapy – 16 treatment groups
2) PEG-IFN monotherapy – 1 treatment group
3) Interferon + ribavarin combination therapy – 6 treatment
groups
4) PEG-IFN + ribavarin combination therapy – 9 treatment
groups
Quantitative Data Synthesis - Non-randomized Studies
Among the 16 interferon monotherapy therapy groups, SVR
ranged from 0% to 76% (median: 37%) with 122 of 342 children
(36%) achieving SVR (Figure 2). In the only study of PEG-IFN
monotherapy, 6 of 14 children (43%) achieved SVR [24]. Among
the 6 interferon/ribavarin combination therapy groups, SVR
ranged from 27% to 64% (median: 48%) with 109 of 233 children
(49%) achieving SVR (Figure 3). Among the 9 PEG-IFN/
ribavarin combination therapy groups, SVR ranged from 30%
to 100% (median: 63%) with 341 of 493 children (69%) achieving
SVR (Figure 4).
Many of the interferon monotherapy studies did not report viral
genotypes. For the interferon/ribavirin case series, the SVR for
genotype 1 ranged from 27% to 53% (median: 40%). Only two
patients among the interferon/ribavirin case series were reported
to have genotype 4, and neither of them responded to therapy.
The SVR for genotypes 2 and 3, which respond more favorably to
treatment than genotypes 1 or 4, was reported in three studies as
84%, 100%, and 100%.
For the PEG-IFN/ribavirin case series where the genotype was
specified, the SVR for genotype 1 ranged from 22% to 100%
(median: 51%) with a combined response of 215/342 (51%) (Table
S1). For genotype 2 or 3, 53 of 54 patients responded (98%) and
for genotype 4, 9 of 12 patients responded in one study (75%) and
80% of patients responded in another study (number of patients
not provided).
Figure 5 shows the SVR in all non-randomized and RCTs
combined, showing improved results with PEG-IFN/ribavirin
(statistics not applied as most studies not randomized).
Discussion
Interferon monotherapy was the initial therapy studied for
pediatric HCV infection and was the focus of 16 studies published
between 1992 and 2003. Multiple dosing regimens of interferon
were studied with the most common being thrice weekly
interferon-alfa for a minimum of 22 weeks. A range of SVR from
0 to 76% from non-randomized studies and a SVR of 45%[18]
and 69% [17] from RCTs was reported. There was only one study
of PEG-IFN monotherapy with a 43% SVR [24]. Adding ribavirin
to interferon was reported in 8 studies published from 2000 to
2007 with a range in SVR from 27% to 64% for the non-
randomized studies and SVR of 59% for the RCT [20].These
therapies are no longer used as standard therapy for adults and are
unlikely to be studied further in children, especially since IFN
Figure 2. SVR of interferon monotherapy in non-randomized studies.
doi:10.1371/journal.pone.0011542.g002
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PEG-IFN. Nonetheless, data on response rates is potentially useful
in situations where children do not tolerate newer therapies.
The current standard of care for adults with chronic HCV is
combination therapy with PEG-IFN and ribavirin [1,15,16]. PEG-
IFN alfa-2b is approved by the US Food and Drug Administration
Figure 3. SVR by genotype of interferon/ribavirin therapy in non-randomized studies. Note the Suoglu study did not report data on
genotype and all patients in the Puetz and Figlerowicz studies were infected with genotype 1.
doi:10.1371/journal.pone.0011542.g003
Figure 4. SVR by genotype of PEG-IFN/ribavirin therapy in non-randomized studies. Note all patients in the Hasan study were infected
with genotype 4 and genotype 1 vs. non-genotype 1 SVR was not reported for the Pawlowska and Sokal studies.
doi:10.1371/journal.pone.0011542.g004
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Medicines Agency with approval of PEG-IFN alfa-2a by the FDA
anticipated to occur soon. In adults, a recent large multicenter
RCT demonstrated no significant difference in the SVR rate
between the two available peginterferon-ribavirin regimens [25].
There were 9 pediatric non-randomized studies of PEG-IFN
with ribavirin with a range in SVR from 30% to 100%. The only
RCT described a 53% SVR [19]. This is certainly no better in
comparison to the 45% to 69% [17,18] and 59% [20] SVR rates
achieved with interferon monotherapy and combination interferon
and ribavirin respectively in RCTs. However, comparison
between trials is clearly flawed given differences in the populations
studied and in particular the lack of comprehensive genotype-
specific outcomes.
The vast majority of children will tolerate PEG-IFN and
ribavirin. Although over half the children in the RCT required
dose reduction of PEG-IFN, it is recognized that dose reduction
was more common in adult trials than it is in clinical practice. The
majority of adverse effects were mild to moderate and the rates of
discontinuation of therapy were low in all groups studied.
As with adult HCV infection, genotype 1 is associated with a
lower response rate to all therapies than is genotype 2 or 3 in
children. In adults, response to therapy with genotype 4 is lower
than with genotype 2 or 3, but there is insufficient pediatric data to
be certain the same principle applies. The proportion of children
with genotype 1 was 81% in the PEG-IFN ribavirin study [19]
versus 70% in the interferon and ribavirin RCT [20] and an
average of 54% in the two interferon monotherapy RCTs [17,18].
The relatively low percentage of children with genotype 1 in the
earlier RCTs may account for the surprisingly high SVRs. The
efficacy of PEG-IFN and ribavirin in children seems comparable
to adults with a SVR of 42% to 46% in adults (versus 47% in the
pediatric RCT) in genotype 1 [15,16], and 76% to 82% in
genotype 2 or 3 in adults (versus 80% for non-genotype 1 in the
pediatric RCT). Based on adult data, African-American ethnicity
is also a risk factor for poor response [26]. Because this was
recognized only recently, a minority of pediatric RCTs or case
series report ethnicity.
In adults, 24 weeks of therapy for genotype 2 or 3 has been
shown to be equivalent to 48 weeks [27]. Currently 48 weeks of
therapy is recommended for all children in American Association
for Study of Liver Disease guidelines regardless of genotype [1] but
a recent small study demonstrated SVR in 16 or 18 children
treated for 24 weeks with genotype 2 or 3 [28]. In adults, failure to
achieve an early virologic response, as defined by at least a 2 log10
drop in HCV RNA at week 12 from baseline, is associated with
non-response [29] and therapy is discontinued. It remains to be
determined if this week 12 stopping rule applies to pediatric
patients.
The current study did not address routine follow-up for children
with HCV infection or when treatment of HCV should be
commenced. It would seem logical to perform clinical follow-up
with measurement of aminotransferases every 3 to 6 months in
children who remain well. However, given the fact that about one-
quarter of adults with significant fibrosis have normal amino-
transferases [1], it remains very controversial if a liver biopsy
should routinely be performed in children after an arbitrary time
period, such as 10 years of HCV infection, even with normal
aminotransferases. Transient elastography (FibroScan H, Echo-
Sens, Paris, France) may ultimately prove useful as a non-invasive
test to identify children who are likely to have fibrosis on biopsy
but this requires further study.
For genotype 1 HCV, new therapies with higher efficacy rates
[30,31]are likely to be licensed soon. We therefore would advise
delaying therapy for genotype 1 HCV unless a biopsy shows
significant fibrosis, or the parent or child is very insistent on
proceeding. It remains controversial if patients with genotypes 2 or
3 who are likely to be compliant and to tolerate therapy should all
Figure 5. SVR and aggregate number of patients included and who achieved SVR by treatment class.
doi:10.1371/journal.pone.0011542.g005
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response rate is over 80% in adults [1] and there are no new
therapies on the horizon. If the decision is made to treat children
with these genotyopes, it would seem reasonable to proceed
without a biopsy. For children over 2 years of age with significant
fibrosis from any genotype, treatment with weight-adjusted doses
of PEG-IFN and ribavirin should be offered, avoiding therapy in
younger children because of the risk of neurotoxicity from
interferon [32]. The decision of when to start therapy must
account for the estimated or known duration of infection,
genotype, degree of fibrosis (particularly in genotype 1), comor-
bidities, predicted compliance, expected adverse events and
anticipated interference with home life, school and extra-
curricular activities. Topical anesthetic creams should be consid-
ered for children with needle phobia. Despite an absence of data,
we recommend using the adult early stopping rules for rapid
responders and non-responders. Monitoring during therapy
should follow adult guidelines [1]. These do not currently
recommend routine ophthalmologic assessments. More pediatric
data is required to determine if this could prevent any long-term
morbidity.
Previous studies have suggested that low baseline serum HCV
RNA predicts successful therapy, and that there is no correlation
between response and pretreatment serum aminotransferase levels
[33]. Recently, a genetic polymorphism near the IL28B gene on
chromosome 19 has been found to be highly predictive of viral
clearance with PEG-IFN and ribavirin, which explains some of the
association between response rate and ethnicity [34]. A limitation
of the current study is that patients could not be stratified by this
polymorphism, age, ethnicity, mode of infection, pretreatment
serum aminotransferase levels, pretreatment serum HCV RNA
levels, or results of liver histology. Future studies should report
these features for all patients in addition to genotype. It would also
be useful to document if there is any risk of later relapse in children
who attain a SVR.
Newer therapies are on the horizon. Phase 3 trials have been
completed in adults with genotype 1 HCV using triple
combination PEG-IFN, ribavirin and the protease inhibitors
telapravir or boceprevir. There is a clear benefit over combination
PEG-IFN and ribavirin, increasing the SVR from 38% to 41%
with dual therapy up to 67% to 75% with triple therapy [30,31]. It
will be vital to collect data on the safety and efficacy of these novel
combination therapies in children. Long-term follow up studies are
also needed to determine the incidence and sequelae of potential
neurotoxicity from PEG-INF in children and the impact of
therapy on morbidity and mortality.
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